NeoImmuneTech Confirms NT-I7’s New Mechanism in Tumor Microenvironment Remodeling — Renewed Spotlight on Long-Term Potential in Combination Immunotherapy

NT-I7 induces tertiary lymphoid structures (TLS), reshaping the tumor immune microenvironment and promoting durable anti-tumor immune responses Supports exploration of NT-I7 in diverse immuno-oncology combination strategies November 25, 2025 — ROCKVILLE, MD : NeoImmuneTech, Inc. (“NIT” or “NeoImmuneTech”), a T-cell-focused immunotherapy company, announced that it presented new research findings on its T cell amplifier, NT-I7 (Efineptakin Alfa), at the Nature Conference: The Tumor Ecosystem – From Bench to Clinic and Back , held from November 19 to 21 (local time) at MD Anderson Cancer Center in Houston, Texas. The conference was hosted by Springer Nature, the publisher of world-renowned scientific journals including Nature , Nature Medicine , and Nature Cancer . The study, led by Assistant Professor, Dr. Rebecca C. Obeng from the Department of Pathology at Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, was selected for both a Flash Talk and a poster presentation under the theme of “Induction of Tertiary Lymphoid Structures (TLS) in the Tumor Immune Microenvironment (TME),” drawing significant attention from the academic community. TLS are small, newly formed immune structures that develop in tumors or inflamed tissues. They serve as local hubs where immune cells gather to initiate and sustain anti-tumor responses. Among these, progenitor exhausted T cells (Tpex) are a stem-like subset capable of self-renewal and differentiation into effector T cells that can re-engage tumor cells, playing a pivotal role in maintaining long-term anti-tumor immunity. According to the study, NT-I7 demonstrated the potential to reprogram the tumor immune microenvironment and induce durable anti-tumor immune responses. Notably, administration of NT-I7 led to a marked increase in lymphoid aggregates, including TLS, around the tumor, with Tpex cells identified within these structures. These findings suggest that NT-I7 may contribute to TLS formation and Tpex maintenance, offering new insights into tumor microenvironment-targeted therapies. This study highlights that NT-I7’s mechanism of action extends beyond simply expanding T cell populations. It provides important evidence that NT-I7 can actively modulate the tumor microenvironment. Given previous research linking TLS and Tpex to improved immunotherapy responses and patient survival, the observed changes in this study underscore NT-I7’s renewed potential in future therapeutic applications. Dr. Donghoon Choi, Chief Scientific Officer at NeoImmuneTech, stated, “This study, along with others, continues to build a strong body of evidence that NT-I7 not only amplifies T cells but also reshapes the tumor microenvironment to support long-term anti-tumor immunity. These findings are consistent with our clinical observations to date and provide a critical scientific foundation for the global development of NT-I7 as an immuno-oncology therapeutic.” NeoImmuneTech remains committed to advancing NT-I7’s mechanism-driven development and will continue to explore its clinical potential to offer new treatment options for cancer patients. *** END ***

The release as fetched from its publisher. neoimmunetech.com ↗